Summary & Overview
HCPCS Level II J9212: Injection, Interferon Alfacon-1, 1 Microgram
HCPCS Level II code J9212 denotes a 1 microgram unit of recombinant interferon alfacon-1 administered by injection. This biologic therapeutic code is relevant nationally for oncology and antiviral care settings where interferon therapies are used. Accurate coding of J9212 is important for clinical documentation, billing consistency, and appropriate benefit determination across public and commercial payers. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical context of interferon alfacon-1 injections, common sites of service, and what to expect in payer coverage considerations. The publication provides benchmarking details, coding and billing guidance items, and notes on policy updates that can affect payment and prior authorization requirements. It also identifies typical service-line placement for this injectable therapy and highlights areas where documentation and unit reporting affect claims processing. Data elements not provided in the input are noted as unavailable.
Billing Code Overview
HCPCS Level II code J9212 describes an injectable biologic: injection, interferon alfacon-1, recombinant, 1 microgram. The service type is therapeutic injection of a recombinant interferon used for clinical indications requiring interferon alfacon-1 administration. The typical site of service is outpatient clinic or physician office where parenteral biologic therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic hepatitis C infection or another off-label viral indication under specialist care who receives prescribed interferon alfacon-1 (recombinant) as a parenteral antiviral therapy. The patient presents to an outpatient infusion clinic or physician office for administration of J9212 (Injection, interferon alfacon-1, recombinant, 1 microgram). Prior to administration, an RN or licensed injector verifies orders, reviews current labs (CBC, liver function tests, thyroid function), confirms informed consent and screening for contraindications (e.g., uncontrolled psychiatric illness, decompensated hepatic disease), and documents baseline vital signs. The medication is prepared per manufacturer guidance and administered subcutaneously or intramuscularly depending on the prescriber’s plan. Post-injection monitoring for acute adverse reactions (fever, myalgias, injection-site reactions) is performed for an appropriate observation period, with discharge instructions and follow-up arranged with the treating specialist. Billing uses J9212 per microgram unit administered with applicable modifiers for unusual circumstances, payer-required place-of-service reporting, and linkage to the treating clinician’s taxonomy and diagnosis codes on the claim.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |